Restricted Area
register »

Program

CIMT 2006 meets Strategies for Immune Therapy

The Agenda will be subject to change until the day of the conference !!!
(March 10)
Cancer Immunotherapy 2006 - Thursday, May 4

  • 08:50-09:00:
    Welcoming Address
    Ch. Huber, Mainz
Session 1:
"Cancer Surveillance – Innate and Adaptive Immunity"
Chairsperson: U. Rapp, Würzburg; C. Melief, Leiden
  • 09:00-09:40:
    "Cancer Immunoediting: Roles for Immunity in Cancer Protection, Persistence and Progression"
    R. Schreiber (St. Louis)


  • 09:40-10:20:
    "Transgenic mice with sporadic immunogenic tumors"
    T. Blankenstein (Berlin)


  • 10:20-11:00:
    "Individuality of the anti-tumor T cell repertoire in melanoma patients"
    T. Wölfel (Mainz)


  • 11:00-11:15:
    Coffee Break
Session 2:
"Tumor associated Immune Suppressions"
Chairperson: T. Blankenstein, Berlin; N.N.
  • 11:15-11:55:
    "L-arginine metabolism and immune dysfunction in cancer"
    V. Bronte (Padua)


  • 11:55-12:35:
    "Cross-targeting to destroy the growth-promoting tumor microenvironment"
    H. Schreiber (Chicago)


  • 12:35-13:15:
    "Strategies to overcome inertia and suppression of tumor specific immune responses"
    C. Melief (Leiden)


  • 13:15-14:15:
    Lunch Break
Poster Session:
Chairperson: N.N.
  • 14:15-16:00:
    Guided Poster Session + Coffee
Session 3:
"Immunmodulatory / Therapeutic Antibodies"
Chairperson: G. Hämmerling; N.N.
  • 16:00-16:40:
    "Siglecs as targets for the regulation of leukocyte function and the elimination of malignant leukocytes"
    G. Fey (Erlangen)


  • 16:40-17:20:
    "Escaping from the T cell: it's PD-L1"
    C. Blank (Regensburg)


  • 17:20-17:55: "Recombinant immunoreceptors to target the T cell immune response"
    H. Abken (Köln)


  • 19:30:
    Dinner at Mollers´Restaurant
Zum Seitenanfang
Scientific Program Meeting 2006 - Friday, May 5

Session 1:
"Therapeutic Vaccination"
Chairperson: P. Walden, Berlin; H. Schreiber, Chicago
  • 08:30-09:10:
    "WT1 peptide-based vaccination generates immunologic responses in peripheral blood and bone marrow associated with antileukemic activity"
    C. Scheibenbogen (Berlin)


  • 09:10-09:50:
    "A rational approach to preclinical development of recombinant cancer vaccines"
    U. Sahin (Mainz)


  • 09:50-10:30:
    "Immunosurveillance at work: Role of Raf as tumor antigen and vaccine target"
    U. Rapp (Wuerzburg)


  • 10:30-11:10:
    "DNA fusion gene vaccination to bypass tolerance"
    F. Stevenson (Southhampton)


  • 11:10-11:25:
    Coffee Break
Session 2:
"Biotech boosts Tumorimmunology"
Chairperson: H.J. Schild, Mainz; N.N.
  • 11:25-11:55:
    "From Targets to Antibody Therapeutics"
    Ö. Türeci (Ganymed)


  • 11:55-12:25:
    "Development of multiple-peptide cancer vaccines"
    H.Singh (Immatics)


  • 12:25-12:55:
    "Towards Cancer Vaccines"
    J. Hess (responsif)


  • 12:55-13:25:
    "Soluble cancer specific monoclonal T cell receptors as protein therapeutics"
    N. MacKenzie (Avidex)


  • 13:25-14:30:
    Lunch Break
Session 3:
"Breaking the Barriers"
Chairperson: Ch. Huber, Mainz
  • 14:30-15:10:
    "Cancer Immunotherapy: Perspectives and Prospects"
    M. Papamichail (Athens)


  • 15:10-15:50:
    "Regulatory Aspects of Immunotherapeutics"
    K. Cichutek (Langen)


  • 15:50-16:30:
    A. Waldmann (Bonn)
Special Features of the meeting:
  • Poster abstracts will be published as supplement to journal CII
  • All Sessions will be available as multi-media files via the homepage
  • 2nd Meeting of the participants of the CIMT Monitoring Panel
  • Press conference after the scientific program
Zum Seitenanfang
Download

Final-Program as PDF-file (595 KB)
 
[ Back ]

ToTop